USPTO serial 97347406
COMPLEGENT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 25, 2023
- Examiner
- THOMAS, JULIE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with COMPLEGENT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal Odedra
Kaushal Odedra ODEDRA LAW OFFICE, PLLC2020 PENNSYLVANIA AVE, NW, #152WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Host cells for medical or clinical use; cells for medical use, namely, cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical use, namely, transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; Pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors being pharmaceutical products for treatment of blood pressure, agents for the treatment of asthma, antitussives and expectorants, stomachics and digestives for pharmaceutical purposes, antacids; hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis; corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, Crohn's disease, and chronic active hepatitis; estrogen and progesterone preparations used as combined oral contraceptives; urinary antiseptics, analgesics, anti-itching agents; cataplasms for the treatment of bruises, lumbago and stiff shoulder; pharmaceutical preparations used to treat hair disorders; vitamin preparations; food enriching agents, namely, vitamin supplements, for treating vitamin deficiencies; anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa rolls and sticks for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs; germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and agricultural use; antiseptics, drugs for treating arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for pharmaceutical in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, drugs for treating Parkinson's disease; pharmaceuticals, namely, minor tranquilizers, and anti anxiety agents; pharmaceuticals, namely, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system; pharmaceuticals, namely, anti-bacterial preparations in the nature of antibacterial substances for medical purposes, monolithic preparations in the nature of substances for medical purposes, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations in the nature of radioactive substances, nutritive substances for microorganisms for medical purposes, pharmaceutical preparations for improving the metabolism and the peripheral circulation, blood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparations; diuretic and anti-hypertensive preparations; in vitro diagnostic reagents for medical use; in vitro extra corporeal diagnostic reagents for medical use; in vitro x-ray contrast agents for medical use; in vitro diagnostic media for medical use, and pharmaceutical preparations for the treatment of insomnia and other sleep related diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 25, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 9, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 9, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 19, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 5, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Mar 31, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Mar 25, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 24, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 23, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 23, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 29, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 25, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Apr 21, 2022 | ALIE | ASSIGNED TO LIE | — |
| Apr 18, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 11, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 8, 2022 | NWAP | NEW APPLICATION ENTERED | — |